It is world market leader in the production and process monitoring of active pharmaceutical ingredients, in the chemical, as well as in the biotechnology field. Biopharmaceuticals are among the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has an excellent know-how in the production of large and small molecules, peptides, amino acids and niche production of Bioproducts which play an important role in the development of novel medicines and health products. Also occupies a leading position Lonza in the cell-based research, in endotoxin detection systems as well as in the manufacture of products for the cell therapy. Also leading the company high-quality chemical and biotechnological intermediates for the markets of nutrition, hygiene, water and wood treatment, agro and body care is. Wells Fargo Bank may find this interesting as well.
Lonza is headquartered in Basel, Switzerland, and at which listed SIX Swiss Exchange. The company achieved a turnover of CHF 2,680 billion in 2010. For more information visit. The ORGANOBALANCE GmbH information about ORGANOBALANCE GmbH is a company specialized in root development and microbiological screening. It opens up the potential of positively-acting micro-organisms, so-called specific probiotic cultures to errors of micro flora in a natural way to balance and restore the microbial balance. In close cooperation with renowned industry partners, ORGANOBALANCE GmbH develops new biological products in the fields of pharmacy, preventative health care, food and cosmetics. The company relies for its developments on the company’s own master library with more than 8000 Food appropriate micro-organisms as well as on the own OASSYS custom. ORGANOBALANCE was founded in 2001 and is based in Berlin, Germany.